Estrogen receptor and breast MR imaging features: A correlation study

被引:56
作者
Chen, Jeon-Hor [1 ,2 ]
Baek, Hyeon-Man [1 ]
Nalcioglu, Orhan [1 ]
Su, Min-Ying [1 ]
机构
[1] Univ Calif Irvine, Sch Med, Ctr Funct Oncoimaging, Irvine, CA 92697 USA
[2] China Med Univ Hosp, Dept Radiol, Taichung, Taiwan
关键词
MR imaging; estrogen receptor; progesterone receptor; breast cancer; invasive ductal carcinoma; MR spectroscopy;
D O I
10.1002/jmri.21330
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To compare the MRI features between estrogen receptor (ER) positive and negative breast cancers. Materials and Methods: Breast MRI of 90 consecutive patients confirmed with invasive ductal carcinoma (IDC), 51 ER positive and 39 ER negative, were analyzed. The tumor morphology and dynamic contrast-enhanced (DCE) kinetics were evaluated based on the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) MRI lexicon and compared. Enlarged axillary lymph nodes on MRI and choline (Cho) detection using MR spectroscopy (MRS) were also analyzed and compared. For patients receiving axillary node dissection the pathological nodal status was also compared. Results: ER negative breast cancer had bigger tumors compared to ER positive cancer (3.6 +/- 2.0 cm vs. 1.8 +/- 1.3 cm, P < 0.00005). ER negative cancer was more likely to exhibit nonmass type enhancements compared to ER positive cancer (P < 0.005). Enlarged axillary lymph nodes were more frequently identified on MRI in ER negative compared to ER positive patients (P < 0.05). After excluding patients undergoing neoadjuvant chemotherapy, axiliary lymph node status did not show significant difference between ER positive and ER negative cancer on MRI and pathology. ER negative cancer was more likely to show the malignant type enhancement kinetics (P = 0.15), rim enhancement (P = 0.15), and Cho detection on MRS (P = 0.23) compared to ER positive cancer, but it did not reach a level of statistical significance. Conclusion: ER negative breast cancer was more aggressive, with larger tumor size, more non-mass-type enhancement lesions, and a higher percentage showing enlarged axillary nodes on MRI. These features might be related to its poorer cellular differentiation and/or a higher angiogenesis.
引用
收藏
页码:825 / 833
页数:9
相关论文
共 43 条
  • [1] Ali SH, 2000, CANCER RES, V60, P7094
  • [2] [Anonymous], 2003, BREAST IM REP DAT SY
  • [3] Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5T
    Baik, Hyun-Man
    Su, Min-Ying
    Yu, Hon
    Mehta, Rita
    Nalcioglu, Orhan
    [J]. MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE, 2006, 19 (02) : 96 - 104
  • [4] Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: Preliminary study
    Bartella, L
    Morris, EA
    Dershaw, DD
    Liberman, L
    Thakur, SB
    Moskowitz, C
    Guido, J
    Huang, W
    [J]. RADIOLOGY, 2006, 239 (03) : 686 - 692
  • [5] Estrogen receptor negative and progesterone receptor positive primary breast cancer:: Pathological characteristics and clinical outcome
    Bernoux, A
    de Cremoux, P
    Lainé-Bidron, C
    Martin, EC
    Asselain, B
    Magdelénat, H
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (03) : 219 - 225
  • [6] In vivo quantification of choline compounds in the breast with 1H MR spectroscopy
    Bolan, PJ
    Meisamy, S
    Baker, EH
    Lin, J
    Emory, T
    Nelson, M
    Everson, LI
    Yee, D
    Garwood, M
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2003, 50 (06) : 1134 - 1143
  • [7] SPATIAL LOCALIZATION IN NMR-SPECTROSCOPY INVIVO
    BOTTOMLEY, PA
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 508 : 333 - 348
  • [8] Survival of patients with metastatic breast carcinoma - Importance of prognostic markers of the primary tumor
    Chang, J
    Clark, GM
    Allred, DC
    Mohsin, S
    Chamness, G
    Elledge, RM
    [J]. CANCER, 2003, 97 (03) : 545 - 553
  • [9] Increased choline kinase activity in human breast carcinomas:: clinical evidence for a potential novel antitumor strategy
    de Molina, AR
    Gutiérrez, R
    Ramos, MA
    Silva, JM
    Silva, J
    Bonilla, F
    Sánchez, JJ
    Lacal, JC
    [J]. ONCOGENE, 2002, 21 (27) : 4317 - 4322
  • [10] Phosphocholine as a biomarker of breast cancer: Molecular and biochemical studies
    Eliyahu, Galit
    Kreizman, Tamar
    Degani, Hadassa
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (08) : 1721 - 1730